Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.
- Conditions
- Coronary Atherosclerosis
- Interventions
- Biological: Blood samplesProcedure: myocardial tissue samplesOther: Data collection
- Registration Number
- NCT05708547
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Brief Summary
Atherosclerosis (deposition of a plaque essentially composed of lipids on the artery walls) is a frequent condition and is a leading cause of death worldwide. In addition to the long-established risk factors such as age, hypertension, diabetes or sedentary lifestyle, it has been demonstrated that immune cells can participate in the genesis of atherosclerotic plaques through metabolic and mitochondrial reprogramming.
A non-invasive marker of this immune reprogramming has yet to be identified. Through the comparison of a group of atheromatous patients and a group of non-atheromatous patients, this study aims to evaluate this reprogramming phenomenon using a novel non-invasive method.
This monocentric interventional study will take place at the Dijon Bourgogne University Hospital and will include 50 patients divided into 2 groups: "atheromatous coronary patients" and "non-atheromatous patients". The duration of participation in this study is 1 month. This study is based on usually performed procedures. Only blood samples will be taken on a catheter usually used during any cardiac surgery in addition to the medical care that is provided during hospitalization.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 50
- Person who provides oral consent
Group 1:
- Patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation
Group 2:
- Patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation
- No coronary lesion
- No peripheral arterial disease (limbs, carotids, aortic aneurysm)
- Person not affiliated with national health care system
- Medication that alters mitochondrial function (Chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil)
- Person under a legal protection measure (curatorship, guardianship, tutorship)
- Pregnant, parturient or breastfeeding women
- Major unable to express consent
- Minor
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Atheromatous coronary patients myocardial tissue samples patients scheduled for coronary artery bypass surgery with extracorporeal circulation Non-atheratomous patients myocardial tissue samples Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease Non-atheratomous patients Data collection Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease Atheromatous coronary patients Data collection patients scheduled for coronary artery bypass surgery with extracorporeal circulation Non-atheratomous patients Blood samples Patients scheduled for valve or ascending aorta surgery with extracorporeal circulation without coronary lesion or peripheral arterial disease Atheromatous coronary patients Blood samples patients scheduled for coronary artery bypass surgery with extracorporeal circulation
- Primary Outcome Measures
Name Time Method Mitophagy level by flow cytometry Before the introduction of extracorporeal circulation. Average fluorescence corresponding to PINK1-AF488 intracellular labelling (mitophagy checkpoint) in conventional (CD33+, CD66b-, CD14++, CD16-), intermediate (CD33+, CD66-, CD14++, CD16+), or non-conventional (CD33+, CD66b-, CD14+, CD16++) monocytes.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chu Dijon Bourgogne
🇫🇷Dijon, France